Welcome to our dedicated page for Third Harmonic Bio news (Ticker: THRD), a resource for investors and traders seeking the latest updates and insights on Third Harmonic Bio stock.
Third Harmonic Bio Inc. (THRD) reports corporate-status and clinical-development updates tied to its stockholder-approved Plan of Liquidation and Dissolution and its THB335 program. The company has operated as a clinical-stage biopharmaceutical developer of highly selective, small-molecule KIT inhibitors for mast-cell-mediated inflammatory diseases affecting dermal, respiratory, and gastrointestinal systems.
Recurring updates include THB335 Phase 1 clinical data, chronic spontaneous urticaria development disclosures, regulatory-readiness activity, operating and financial results, shareholder voting matters, governance actions, and capital-structure developments connected with the company's liquidation and dissolution process.
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, announced that its CEO, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 7:30 a.m. ET.
The event will be webcast live on the Third Harmonic Bio website, with a replay available for 90 days post-event.
The company focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases.
Third Harmonic Bio (Nasdaq: THRD) announced its Q1 2024 financial results and business updates. The U.S. FDA cleared its IND application for THB335, enabling a Phase 1 clinical trial focusing on chronic spontaneous urticaria. Results are expected in the first half of 2025. The company strengthened its leadership, appointing Christopher J. Dinsmore, Ph.D., as Chief Scientific Officer, Dennis Dean, Ph.D., as Chief Non-Clinical Development Officer, and promoting Jennifer Dittman to Chief Development Operations Officer. Financially, the company reported cash and equivalents of $262.8 million, decreased R&D expenses to $6.2 million, and G&A expenses to $5.1 million. Net loss decreased to $7.9 million from $9.1 million a year earlier.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.